- Home
- RFI vs PROK Comparison
RFI vs PROK Comparison
Compare RFI & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFI | PROK |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 359.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RFI | PROK |
|---|---|---|
| Price | $11.12 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 110.2K | ★ 921.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $10.78 | $0.54 |
| 52 Week High | $12.18 | $7.13 |
Technical Indicators
Market Signals| Indicator | RFI | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 55.14 |
| Support Level | $11.07 | $1.73 |
| Resistance Level | $11.35 | $1.96 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 20.45 | 62.83 |
Price Performance
Historical ComparisonAbout RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.